Ebola virus was first discovered in 1976 in the Democratic Republic of Congo (DRC). Since then, the virus has been infecting people, leading to outbreaks in several African countries. It is a severe disease caused by the Ebola virus, a member of the filovirus family, which occurs in humans and other primates. Scientists do not know where the Ebola virus comes from, they believe the Ebola virus came from the animal. According to the Centers for Disease Control and Prevention (CDC), the most expected sources are non-human primates or bats.
Symptoms include weakness, lack of appetite, sore throat, muscle and joint pain, abdominal pain, fever, and headache. The Ebola outbreak devastated countries across West Africa from 2013 to 2015. With no vaccine to curb its spread, the disease claimed more than 11,000 lives. This in turn is expected to increase the demand for the Ebola vaccine, driving the Ebola vaccine market growth. For example, on December 19, 2019, the U.S. Food and Drug Administration (FDA) announced the approval of Ervebo, the first FDA-approved vaccine for the prevention of Ebola virus disease (EVD).
Moreover, ZEBOV/MVA-BN-Filo and rVSV-ZEBOV are two vaccines that have recently received regulatory approval. rVSV-ZEBOV, a single-dose vaccine, made by Merck; and the two-dose Ad26. ZEBOV/MVA-BN-Filo, made by Janssen Vaccines and Prevention. Ebola vaccines are vaccines either approved or in development to prevent Ebola. This in turn is also expected to augment the growth of the Ebola vaccine market. Ebola is a life-threatening disease, which causes viral hemorrhagic fever. It may cause due to direct contact with the body fluids of an infected individual.
Ebola virus disease, formerly known as Ebola hemorrhagic fever, is a rare but severe, often fatal illness in humans. Currently, most of the Ebola vaccines are under different developmental stages. The major driving factor for the growth of the Ebola vaccine market is the increase in mortality due to the Ebola virus. According to World Health Organization (WHO), around 50% of people infected with the Ebola virus disease have died in January 2018. Thus, there is an increasing demand for Ebola vaccines all over the world.
After the outbreak was declared in August 2018, the virus-infected around 3,470 people, killing around 66% of them. That makes it the world's second-largest outbreak of hemorrhagic disease, after the 2014-16 West Africa epidemic, which killed more than 11,000 people. New outbreaks of Ebola are expected in the Democratic Republic of Congo given the existence of the virus in an animal reservoir in many parts of the country. As of 31 May 2020, around 3195 new cases of EVD have been reported, including 72 deaths. This in turn is also expected to increase the Ebola vaccine demand, driving the growth of the Ebola vaccine market.